ADM Endeavors, Inc.

ADM Endeavors, Inc. operates as Cardima, a medical device company specializing in the diagnosis and treatment of cardiac arrhythmias. Cardiac arrhythmias are conditions caused by abnormal electrical currents in the heart, leading to fast, slow, or irregular heartbeats, which can be symptomatic and associated with significant health issues. The company's primary focus is on atrial fibrillation (AF) and ventricular tachycardia (VT), with most clinical and commercial efforts dedicated to AF. ADM Endeavors' product portfolio includes the PATHFINDER® and REVELATION® Series of diagnostic catheters, the VUEPORT® and NAVIPORT® Series of guiding catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System. All these devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION® Series of ablation catheters, when used with the INTELLITEMP® EP Energy Management Device for treating AF, has CE mark approval and is marketed in Europe. The INTELLITEMP® device has also received approval from the Chinese State Food and Drug Administration (SFDA) for marketing in the People's Republic of China. Key registered trademarks include PATHFINDER®, TRACER™, VUEPORT®, NAVIPORT®, REVELATION®, and INTELLITEMP®. The PATHFINDER® Series of microcatheters are small, flexible wire-based devices designed for accessing and mapping in the coronary sinus during difficult procedures. The company's linear ablation systems for EP and surgical ablation deliver controlled radiofrequency (RF) energy to create thin, continuous, linear, transmural lesions.